Skip to main content

Table 6 Segmented regression analysis for vascular protective and comparator medication coverage, 2010 to 2016, administrative cohort

From: Impact of the diabetes Canada guideline dissemination strategy on dispensed vascular protective medications for older patients in Ontario, Canada: a linked EMR and administrative data study

VariableEstimateSEPvalue
STATIN
 Baseline prescription rate60.990.31<.0001
 Pre-intervention slope0.200.04<.0001
 Change at guideline (2013Q2)−0.260.390.51
 Slope change− 0.120.050.04
ACEI or ARB
 Baseline prescription rate62.160.23<.0001
 Pre-intervention slope−0.130.030.0001
 Change at guideline (2013Q2)0.210.290.46
 Slope change0.000.040.99
Antiplatelet
 Baseline prescription rate10.460.08<.0001
 Pre-intervention slope−0.120.01<.0001
 Change at guideline (2013Q2)−0.090.080.29
 Slope change−0.030.010.03
PPI
 Baseline prescription rate22.670.18<.0001
 Pre-intervention slope0.220.02<.0001
 Change at guideline (2013Q2)0.090.210.67
 Slope change−0.110.030.002